Also, decreasing tau acetylation at Lys174 alleviates cognitive impairments and tau-mediated neurodegeneration (Min et al. 2015), indicating that reducing soluble tau forms is effective in enhancing cognitive function (de Calignon et al. 2010), (Caballero et al. 2021). The gene discussed is MAPT; the disease is Cognitive impairment.